{"filings":[{"id":97436,"accession_number":"0001213900-26-048687","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Drugs Made In America Acquisition II Corp. updates CFO and CEO compensation, grants equity upon business combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Saleem Elmasri's monthly fee remains $3,500; equity grant increases from 100,000 to 175,000 shares earned at execution of definitive agreement.","CEO Roger Bendelac receives $4,500/month ($2,500 current, $2,000 deferred) and 250,000 shares earned upon signing a definitive business combination agreement.","Both equity grants are to be issued at closing of the initial business combination, within ten days thereafter.","Updated Statement of Work with Titan Advisory Services LLC and CEO Compensation Agreement with Aleutian Equity Holdings LLC were entered on April 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97435,"accession_number":"0001213900-26-039986","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DMIIU enters $1.4M convertible note agreement for de-SPAC financing; issues $300K interim note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total financing commitment of $1.4M; $150K already received, $300K funded on March 30, 2026 as interim convertible note.","Conversion at 35% discount to post-merger market value at investor's discretion; nine-month maturity.","Proceeds used for audit, accounting, SEC, Nasdaq fees, legal costs, and transaction preparation.","Existing sponsor non-performing; investor has right to acquire sponsor interests when legally permitted.","Exclusivity period of six months to complete de-SPAC transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112219,"accession_number":"0001213900-26-029050","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","8.01","2.03","9.01"],"status":"ready","headline":"Drugs Made In America Acquisition II Corp. issues $150K convertible bridge note as part of $1.4M financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On March 11, 2026, Company issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office (Investor).","The bridge note is part of a larger $1,400,000 convertible notes financing under a Letter of Intent dated March 5, 2026 and an addendum dated March 9, 2026.","The note matures nine months from issuance, bears no interest, and is convertible at a 35% discount to market price upon a business combination.","The Company plans to use proceeds for accounting, audit, and other expenses related to the business combination.","The LOI originally contemplated $1,500,000 but was reduced to $1,400,000 after $100,000 in advisor fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112218,"accession_number":"0001213900-26-024763","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Drugs Made In America Acquisition II confirms trust account of ~$507.8M after sponsor irregularities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsor made improper withdrawals from working capital between Sep 26, 2025 IPO and Dec 31, 2025.","Board confirmed irregularities did not affect trust account.","As of March 6, 2026, trust account balance is approximately $507,841,957.","The trust account protects public shareholders; no prior disclosure of exact balance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112217,"accession_number":"0001213900-26-024387","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DMIIU CEO Lynn Stockwell resigns after Sponsor fails to repay $566K overpayment; Roger Bendelac appointed CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lynn Stockwell resigned as CEO, Executive Chair, and Board member on Feb 28, 2026, after Board learned Sponsor could not repay $566,269 overpayment.","Board accepted resignation and removed Stockwell from all positions effective Feb 28, 2026.","Roger Bendelac, 69, with 30+ years in investment banking and advisory, appointed CEO effective Feb 28, 2026.","Sponsor withdrew $1.1M from working capital; $566K+ used for expenses unrelated to the Company and not repaid.","Bendelac's compensation not yet determined; Board will consider and disclose terms later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128791,"accession_number":"0001213900-25-111706","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Drugs Made In America Acquisition II Corp. appoints Saleem Elmasri as CFO after Glenn Worman resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn Worman resigned as CFO and principal financial and accounting officer effective October 8, 2025, with no disagreement with the company.","Saleem Elmasri was appointed CFO effective November 17, 2025, under a consulting agreement with Titan Advisory Services LLC.","Compensation includes $42,000 per year ($3,500 per month) plus 100,000 ordinary shares transferred by CEO Lynn Stockwell.","Elmasri is a CPA with 20 years experience, previously at PwC and as Managing Partner of Titan Advisory Services LLC since 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128790,"accession_number":"0001213900-25-095513","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Drugs Made In America Acquisition II closes $500M IPO and $12M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 50M units at $10 each grossed $500M; units trade on Nasdaq (DMIIU).","Private placement of 1.2M units to sponsor and Cantor Fitzgerald raised $12M.","$500M deposited into trust account; company has 24 months to complete initial business combination.","Balance sheet: $1.58M cash, $17.5M deferred underwriting liability, $17.2M accumulated deficit.","Auditor includes going concern qualification due to mandatory liquidation if no business combination within 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145543,"accession_number":"0001213900-25-093224","cik":2040475,"company_name":"Drugs Made In America Acquisition II Corp.","ticker":"DMII","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","8.01","9.01"],"status":"ready","headline":"SPAC Drugs Made In America Acquisition II Corp. closes $500M IPO; $500M in trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced and closed IPO of 50M units at $10/unit for gross proceeds of $500M.","Concurrent private placement of 1.2M units ($12M) to sponsor and Cantor Fitzgerald.","Net proceeds of $500M deposited into trust account for public shareholders.","Units trade on Nasdaq under DMIIU; ordinary shares and rights to trade separately later.","Appointed Catherine Do, G. Sridhar Prasad, Myron W. Shulgan to board and committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":641458988.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}